gsk

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026 GSK plc (LSE/NYSE: GSK) today announced positive results ...
gsk

Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B

GSK plc (LSE/NYSE: GSK) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Hibsago (bepirovirsen), an antisense oligonucleotide (ASO), as a functional cure for ...
gsk

GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK

GSK plc (LSE/NYSE: GSK) today announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot ...
gsk

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts ...

Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%) Vaccines sales £2.3 billion (+8%) ...
gsk

European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds

GSK plc (LSE/NYSE: GSK) today announced the European Medicines Agency (EMA) has accepted a submission to update the label for Bexsero to include a single dose booster for individuals aged 10 years and ...
gsk

GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)

GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in ...
gsk

GSK announces commencement of tender offer to acquire Nuvalent, Inc.

GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. (“Purchaser”), a direct wholly-owned subsidiary of ‎GlaxoSmithKline LLC (“GSK LLC”), which is an ‎indirect wholly-owned ...
gsk

GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch

Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China Chronic hepatitis B affects 75 million people in China and is a national health ...
gsk

GSK delivers strong Q1 performance and start to 2026

Luke Miels, Chief Executive Officer, GSK: “GSK has made a strong start to 2026, with good performance from our key growth drivers. Alongside operational delivery, we are focused on execution and ...
gsk

GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH

Phase II data show once-monthly efimosfermin improved liver fibrosis (scarring), a key driver of disease progression in metabolic dysfunction-associated steatohepatitis (MASH) MASH is a leading cause ...
gsk

GSK completes acquisition of RAPT Therapeutics

GSK plc (LSE/NYSE: GSK) today announced the completion of its previously announced acquisition of RAPT Therapeutics, a California-based, clinical-stage biopharmaceutical company dedicated to ...
gsk

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission

Prefilled syringe offers healthcare professionals a convenient administration option New presentation will begin rolling out across EU countries in 2026 Shingles affects approximately 1.7 million ...